
BioNTech SE (BNTX) Stock Forecast & Price Target
BioNTech SE (BNTX) Analyst Ratings
Bulls say
BioNTech has maintained a robust financial position, ending the third quarter of 2025 with approximately €16.7 billion in cash, cash equivalents, marketable securities, and trade receivables, which supports its ongoing research and development initiatives. The incremental positive news surrounding its BNT323 drug candidate for breast cancer indicates a promising outlook as it enters global Phase 3 clinical trials, potentially expanding its oncology pipeline. Moreover, the company has made headway with its LP.8.1-adapted monovalent COVID-19 vaccine, showing improved immune responses against various circulating SARS-CoV-2 sublineages, underscoring its continued relevance in the vaccine market alongside its ambitious therapeutic pursuits.
Bears say
BioNTech faces numerous risks that contribute to a negative outlook, including potential negative clinical data from several of its cancer therapeutics and slower-than-expected market uptake of its products. The company reported a net loss per diluted share of €0.12 in the third quarter of 2025, with projected full-year losses reaching €3.99 per share, signaling financial difficulties. Additionally, investor focus may remain on the challenges posed by a shifting landscape in the COVID-19 vaccine market, particularly due to regulatory changes in the U.S., overshadowing BioNTech's oncology pipeline developments.
This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.
BioNTech SE (BNTX) Analyst Forecast & Price Prediction
Start investing in BioNTech SE (BNTX)
Order type
Buy in
Order amount
Est. shares
0 shares